For research use only. Not for therapeutic Use.
YG1702 is a potent ALDH18A1-specific inhibitor. YG1702 attenuates the growth of MYCN-amplified NB and down-regulates MYCN. YG1702 physically interacts with ALDH18A1 with a high affinity and might potentially affect its enzymatic activity[1].
YG1702 (intraperitoneal injection (I.P.), 45 mg/kg, once every 3 days, three times) inhibits the growth of the xenografts in tumor-bearing mice[1].
| Catalog Number | I040554 |
| CAS Number | 724737-08-0 |
| Synonyms | 3-O-(2-methoxyethyl) 5-O-(2-propan-2-ylsulfanylethyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| Molecular Formula | C23H30N2O7S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H30N2O7S/c1-14(2)33-13-12-32-23(27)20-16(4)24-15(3)19(22(26)31-11-10-30-5)21(20)17-8-6-7-9-18(17)25(28)29/h6-9,14,21,24H,10-13H2,1-5H3 |
| InChIKey | WBMJXHUWKGEKBB-UHFFFAOYSA-N |
| SMILES | CC1=C(C(C(=C(N1)C)C(=O)OCCSC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OCCOC |
| Reference | [1]. Guo YF, et al. Inhibition of the ALDH18A1-MYCN positive feedback loop attenuates MYCN-amplified neuroblastoma growth. Sci Transl Med. 2020 Feb 19;12(531):eaax8694. |
